PAK1-blocking 1,2,3-triazolyl esters
US10058618B2 · kind B2 · utility
0Cited by
0References
15Claims
0Family size
Inventors
Key dates
| Filing date | Nov 30, 2016 |
| Grant date | Aug 28, 2018 |
| Priority date | — |
| Expiry date | Nov 30, 2036 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a PAK1 blocking compound having a much higher bioavailability and cell permeability than traditional herbal PAK1 blockers or synthetic PAK1 blockers, and the uses thereof for treating cancer or other PAK1 dependent diseases or disorders. This PAK1 blocking compound comprises an ester of an acidic PAK1 blocker, or a pharmaceutically acceptable salt thereof. This PAK1-blocking ester may be prepared by esterifying a PAK1 blocker starting material with an alcohol; and treating the esterified PAK1 blocker with an aromatic azide to generate a 1,2,3-triazolyl derivative.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.